Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hallervorden-Spatz syndrome.

K F Swaiman1

  • 1Division of Pediatric Neurology, Department of Neurology, University of Minnesota, Minneapolis, USA.

Pediatric Neurology
|September 12, 2001
PubMed
Summary
This summary is machine-generated.

Hallervorden-Spatz syndrome diagnosis and therapies are evolving. A PANK2 gene defect offers new hope for understanding and treating this neurodegenerative disorder.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The organization of the Child Neurology Society: a personal view.

Pediatric neurology·1996
Same author

Neurologic characteristics of childhood lupus erythematosus.

Pediatric neurology·1995
Same author

Effect of ferric nitrilotriacetate on rostral mesencephalic cells.

Neurochemical research·1991
Same author

Hallervorden-Spatz syndrome and brain iron metabolism.

Archives of neurology·1991
Same author

Effects of phenobarbital and phenytoin on cortical glial cells in culture.

Brain & development·1991
Same author

Effect of ferric nitrilotriacetate on predominantly cortical glial cell cultures.

Neurochemical research·1990

Area of Science:

  • Neurology
  • Genetics
  • Neurodegenerative Diseases

Background:

  • Hallervorden-Spatz syndrome (HSS) diagnosis and classification have historically faced challenges.
  • Current symptomatic therapies for HSS exist but require optimal patient-specific application.
  • Limited understanding of HSS pathophysiology has impeded definitive treatment development.

Purpose of the Study:

  • To review the current status of Hallervorden-Spatz syndrome diagnosis, classification, and therapies.
  • To highlight recent genetic findings and their implications for future research and treatment.
  • To emphasize the need for further investigation into the syndrome's underlying mechanisms.

Main Methods:

  • Literature review of historical and current data on Hallervorden-Spatz syndrome.

Related Experiment Videos

  • Discussion of identified gene loci and their association with the syndrome.
  • Analysis of the impact of recent genetic discoveries on HSS understanding.

    • Main Results:

    • While symptomatic therapies are available, many HSS patients do not link to the NBIA1 locus.
    • A defect in the PANK2 gene has been identified in Hallervorden-Spatz syndrome patients.
    • Oxidative stress is implicated in the syndrome's pathophysiology.

    Conclusions:

    • The identification of the PANK2 gene defect is a significant advancement for HSS diagnosis and management.
    • Further research into the syndrome's basic mechanisms, including oxidative stress, is crucial.
    • Improved understanding will facilitate more meaningful classification and definitive therapies for Hallervorden-Spatz syndrome.